---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000065"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:50:52.418360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%

## Summary
- Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.
- Total revenue $175.7M (+14% YoY); operating earnings $40.9M; adjusted operating earnings $67.7M.
- Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).
- SPN-820 Phase 2a in MDD: rapid decrease in depressive symptoms, 80% decrease in suicidal ideation; Phase 2b data H1 2025.
- SPN-817 Phase 2a in treatment-resistant seizures: 56% median seizure reduction; Phase 2b expected start by end 2024.

## SEC filing metadata
- accession: 0001356576-24-000065
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000065/0001356576-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000065/supn-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000065
- JSON: https://secwatch.observer/filing/0001356576-24-000065.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.